Welcome to our dedicated page for Bachem Holding news (Ticker: BCHMY), a resource for investors and traders seeking the latest updates and insights on Bachem Holding stock.
The Bachem Holding AG (BCHMY) news page on Stock Titan aggregates company announcements and market-relevant updates for investors following this ADR. Bachem, whose primary listing is on the SIX Swiss Exchange, describes itself as a specialist in the development and manufacture of peptides and oligonucleotides, supplying pharmaceutical and biotechnology companies worldwide from its headquarters in Switzerland and sites in Europe, the US, and Asia.
News about Bachem frequently covers financial results, such as half-year and full-year sales, EBITDA margins, and performance by product category including Commercial API, CMC Development, and Research & Specialties. These releases often discuss demand trends for peptide and oligonucleotide projects, operational execution across the company’s manufacturing network, and guidance for future growth in local currencies.
Another recurring theme in Bachem’s news is capacity expansion. Updates describe progress on Building “K” in Bubendorf, which the company calls its most advanced and largest production plant for large volumes of peptides and oligonucleotides, as well as plans for a new manufacturing site in Sisslerfeld. Announcements also highlight investments in U.S. sites at Vista and Torrance and in Vionnaz in Western Switzerland.
Corporate governance and leadership developments are also reported, including Annual General Meeting outcomes, dividend decisions, changes to the Board of Directors, and adjustments to the Corporate Executive Committee and COO role. By reviewing this news feed, readers can follow how Bachem communicates its strategy, investment program, and operational milestones that affect its position as a peptide and oligonucleotide manufacturer.
Bachem (SIX: BANB) has announced that Dr. Simone Wyss Fedele will be recommended for election to the Board of Directors at the Annual General Meeting on April 30, 2025. Dr. Wyss Fedele, currently CEO of Switzerland Global Enterprise (S-GE), brings extensive experience in the life science industry and international business.
Dr. Wyss Fedele's background includes leadership roles at Novartis International as Chief Economist and Head of Public Affairs, and at Takeda Pharmaceuticals as Commercial Lead and Head of Market Access for Europe and Canada. She holds positions on various prestigious boards, including the WEF Global Future Councils and the Swiss National Bank's Regional Council Northwest Switzerland.
All current board members will stand for re-election. The company has also announced key upcoming dates, including the dividend payout date on May 7, 2025, and the Half-Year Report 2025 publication on July 24, 2025.
Bachem (SIX: BANB) reported strong financial results for 2024, with group sales increasing 4.8% to CHF 605.3 million and EBITDA rising 5.7% to CHF 176.3 million. The company achieved an EBITDA margin of 29.1% and net income growth of 7.5% to CHF 120.2 million.
Sales performance across categories showed positive momentum: Commercial API sales grew 5.8% to CHF 327.0 million, CMC Development increased 3.0% to CHF 234.4 million, and Research & Specialties rose 7.5% to CHF 43.8 million.
The company invested CHF 292.2 million in capacity expansion in 2024, including progress on building 'K' in Bubendorf, set to begin test batch production in Q2 2025. Bachem targets 10-15% growth in local currencies for 2025, with planned CAPEX investments exceeding CHF 400 million. The company aims to achieve annual sales of over CHF 1 billion with an EBITDA margin above 30% by 2026.
Bachem Group (SIX: BANB) reported a slight sales growth of 0.2% to CHF 240.3 million in the first half of 2024, with a 1.3% increase in local currencies. EBITDA rose by 5.6% to CHF 55.5 million, with a margin of 23.1%. The company expects mid- to high-single-digit percentage growth in local currencies for 2024, maintaining a stable EBITDA margin. Bachem aims for annual sales exceeding CHF 1 billion and an EBITDA margin over 30% by 2026.
Sales in the Commercial API category declined by 13.4%, while CMC Development saw an 18.7% increase. The company is expanding production capacities globally, with significant investments across all sites. Bachem has begun commissioning equipment in its largest production plant for peptides and oligonucleotides in Bubendorf and is planning a new manufacturing site in Eiken.